Free Trial

Stelrad Group (SRAD) Competitors

GBX 144 +1.00 (+0.70%)
As of 11:57 AM Eastern

SRAD vs. DOCS, WIX, YOU, CNIC, SLP, NET, GVP, ARBB, CYN, and INSE

Should you be buying Stelrad Group stock or one of its competitors? The main competitors of Stelrad Group include Dr. Martens (DOCS), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Sylvania Platinum (SLP), Netcall (NET), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), CQS Natural Resources Growth and Income (CYN), and Inspired (INSE). These companies are all part of the "computer software" industry.

Stelrad Group vs. Its Competitors

Stelrad Group (LON:SRAD) and Dr. Martens (LON:DOCS) are both small-cap industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 28.08% beat Dr. Martens' return on equity.

Company Net Margins Return on Equity Return on Assets
Stelrad Group5.25% 28.08% 7.46%
Dr. Martens 7.89%18.91%8.12%

Dr. Martens has higher revenue and earnings than Stelrad Group. Dr. Martens is trading at a lower price-to-earnings ratio than Stelrad Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stelrad Group£306.97M0.62£16.13M£11.6412.37
Dr. Martens£874.20M0.85£68.97M£7.0510.84

Stelrad Group has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Dr. Martens has a consensus target price of GBX 6,000, indicating a potential upside of 7,743.14%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Stelrad Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stelrad Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Dr. Martens
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

35.5% of Stelrad Group shares are owned by institutional investors. Comparatively, 69.5% of Dr. Martens shares are owned by institutional investors. 64.4% of Stelrad Group shares are owned by company insiders. Comparatively, 4.4% of Dr. Martens shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Stelrad Group pays an annual dividend of GBX 8 per share and has a dividend yield of 5.6%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.9%. Stelrad Group pays out 68.7% of its earnings in the form of a dividend. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Dr. Martens had 17 more articles in the media than Stelrad Group. MarketBeat recorded 17 mentions for Dr. Martens and 0 mentions for Stelrad Group. Dr. Martens' average media sentiment score of 0.40 beat Stelrad Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company Overall Sentiment
Stelrad Group Neutral
Dr. Martens Neutral

Dr. Martens received 11 more outperform votes than Stelrad Group when rated by MarketBeat users. Likewise, 84.62% of users gave Dr. Martens an outperform vote while only 0.00% of users gave Stelrad Group an outperform vote.

CompanyUnderperformOutperform
Stelrad GroupOutperform Votes
No Votes
Underperform Votes
1
100.00%
Dr. MartensOutperform Votes
11
84.62%
Underperform Votes
2
15.38%

Summary

Dr. Martens beats Stelrad Group on 13 of the 19 factors compared between the two stocks.

Get Stelrad Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRAD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRAD vs. The Competition

MetricStelrad GroupBuilding Products & Equipment IndustryIndustrials SectorLON Exchange
Market Cap£191.30M£3.58B£7.79B£2.93B
Dividend Yield5.31%3.03%4.56%4.90%
P/E Ratio12.3752.8425.41125.70
Price / Sales0.6287.42118.39243,028.71
Price / Cash12.5517.0726.8428.07
Price / Book3.341.764.224.76
Net Income£16.13M£18.85B£807.24M£5.91B
7 Day Performance-0.69%0.45%1.28%13.21%
1 Month Performance11.20%2.16%9.37%16.80%
1 Year Performance21.41%2.50%25.58%78.27%

Stelrad Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRAD
Stelrad Group
N/AGBX 144
+0.7%
N/A+19.9%£191.30M£306.97M12.372,960Gap Down
DOCS
Dr. Martens
3.2644 of 5 stars
GBX 59.95
+0.7%
GBX 6,000
+9,908.3%
-5.0%£581.97M£874.20M8.50890Earnings Report
Dividend Cut
WIX
Wickes Group
1.7639 of 5 stars
GBX 224.50
-0.9%
GBX 215
-4.2%
+60.0%£531.55M£1.45B18.155,930
YOU
YouGov
2.9258 of 5 stars
GBX 326.50
+1.2%
GBX 880
+169.5%
-60.1%£382.05M£335.28M-166.401,820Gap Down
CNIC
CentralNic Group
N/AN/AN/AN/A£339.82M£790.04M-12,660.00100
SLP
Sylvania Platinum
N/AGBX 60.80
+1.3%
N/A+15.8%£196.22M£99.97M28.49160News Coverage
NET
Netcall
1.7667 of 5 stars
GBX 108
+4.3%
GBX 130
+20.4%
+32.2%£178.52M£39.16M30.413,220
GVP
Gabelli Value Plus+ Trust
N/AN/AN/AN/A£155.29MN/A0.00310Gap Down
ARBB
Arbuthnot Banking Group
N/AGBX 945
+1.6%
N/A+2.8%£152.96M£239.83M5.00799
CYN
CQS Natural Resources Growth and Income
N/AGBX 202
+1.0%
N/A+8.1%£127.02M£12.63M14.3640News Coverage
Positive News
INSE
Inspired
N/AGBX 75
-0.7%
N/A-12.5%£119.73M£155.87M68.671,600

Related Companies and Tools


This page (LON:SRAD) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners